ClinicalTrials.govpublic full text
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
advanced lymphoma, advanced malignant solid neoplasm, hematopoietic and lymphoid cell neoplasm, refractory lymphoma, refractory malignant solid neoplasm, refractory multiple myeloma, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 861735
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.